Phase 2 Completed N=44 Randomized Single-blind Basic Science

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine

Healthy

Source: ClinicalTrials.gov NCT04138615 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2023

Primary outcomePrimary: Tolerance to Simulated Hemorrhage — 385; 692 CSI: Cumulative Stress Index

Summary

We are examining how morphine (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in our research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

Outcome Measures

Outcome	Result	p-value
PRIMARY Tolerance to Simulated Hemorrhage	385; 692	—
SECONDARY Pain Assessment - Algometer	1.1; 0.9	—

Eligibility Criteria

Inclusion Criteria

Healthy
Non-obese (body mass index less than 30 kg/m2)
Body mass greater than or equal to 65 kg

Exclusion Criteria

Subjects who have cardiac, respiratory, neurological and/or metabolic illnesses
Any known history of renal or hepatic insufficiency/disease
Pregnancy or breast feeding
Current smokers, as well as individuals who regularly smoked within the past 3 years
Positive urine drug screen
Currently taking pain modifying medication(s)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04138615). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.